Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of surfactant protein A-derived peptidomimetics for the treatment of asthma

Award Number: R41HL152942
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2022

Group Awards By:

View Award Description

Development of surfactant protein A-derived peptidomimetics for the treatment of asthma - Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. There is no current innate immune modulator for the treatment of asthma. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. The cause of an exacerbation is often an infection in the setting of abnormal airway inflammation. The response to infection is complex, involving both the innate and adaptive immune systems. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivity account for $21 billion/year in US annual health care expenditures. Thus, there is a critical need to develop new therapies to be used in the treatment of inflammatory lung diseases including asthma. The objective of this Phase I proposal is to develop new short peptide derivatives and mimetics of the active region of surfactant protein-A (SP-A), a protein that regulates key innate immune functions in the lung, and perform a drug screen that identifies those most active and stable with similar efficacy as the full-length protein. SP-A-derived peptides do not occur naturally and by synthetically produced analogs, we can create custom modifications with improved pharmacokinetic properties and stability. We will use asthma as our test model where SP-A peptide analogs modulate eosinophil and epithelial cell functions, key targets where cellular mechanisms drive the allergic asthma phenotype. The rationale for this study is based on our findings that the SP-A peptide reduces airway hyperresponsiveness (AHR), a fundamental characteristic of asthma, in two different pre-clinical mouse models of asthma. We have strong evidence to support that the mechanisms of protective action are due to 1) direct interaction with eosinophils to induce apoptosis and promote their resolution from the airway and 2) direct interaction with epithelial cells to inhibit mucin production. Therefore, our central hypothesis is that through direct effects upon airway eosinophil and epithelial cells, SP-A-derived peptides reduce airway inflammation and hyperresponsiveness associated with asthma. We propose to test this hypothesis through two specific aims. In Aim 1 we will synthesize, engineer and optimize peptides and structural mimetics derived from SP-A to identify a lead mimetic. In aim 2 we will characterize the bioactivity of SP-A-derived peptides and mimetics at specific cellular targets to identify a lead compound using a high throughput. Our company, RaeSedo LLC, was founded on the principle that we can create custom modifications with improved pharmacokinetic properties and stability for the development of this new class of asthma therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2020	RAESEDO LLC	5435 N KENNEBEC LN	TUCSON	AZ	85704	PIMA	USA	Lung Diseases Research	000	1	10/12/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $214,912 )
2020	2020	RAESEDO, LLC	5435 N KENNEBEC LN	TUCSON	AZ	85704	PIMA	USA	Lung Diseases Research	000	1	7/13/2020	NEW	$214,912
														Subtotal = $214,912

Grand Total All Awards = $214,912

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of surfactant protein A-derived peptidomimetics for the treatment of asthma

Award Number: R41HL152942

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer